



\$RCE/1651
Patent #12
LP
Attorney's Docket No. 001560-381

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Kengo AKIMOTO et al.) Group Art Unit: 1651
Application No.: 09/530,260) Examiner: Irene Marx
Filed: July 12, 2000) Confirmation No.: 7267
For: PROCESS FOR PRODUCING)
ARACHIDONIC ACID-)
CONTAINING LIPID AND)
DIHOMO-GAMMA-LINOLENIC)
ACID-CONTAINING LIPID)

RECEIVED

APR 01 2003

REQUEST FOR CONTINUED EXAMINATION
TRANSMITTAL LETTER

TECH CENTER 1600/2900

BOX RCE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicant(s) requests continued examination under 37 C.F.R. § 1.114 and enclose the [] \$375.00 (2801) [X] \$750.00 (1801) fee due under 37 C.F.R. § 1.17(e).

1. Applicant(s) previously submitted the following documents for which continued examination is requested:
[X] Consider the Amendment and Reply under 37 C.F.R. § 1.116 previously filed on January 27, 2003.
[] Consider the arguments in the Appeal Brief or Reply Brief previously filed on ____.
[] Other: _____
2. The following documents are enclosed with this submission:
[X] Supplemental Reply and Declaration Pursuant to 37 C.F.R. §§ 1.801-1.809.
[] Affidavit(s)/Declaration(s).
[] Information Disclosure Statement (IDS).
[] Other: _____
3. [] Small entity status is hereby claimed.
[] No additional claim fee is required.
[] The fee is calculated below on the basis of the highest number of claims already paid for in this application prior to this submission:

03/31/2003 AWDNDAF1 00000076 09530260

01 FC:1801

750.00 0P



21839

(10/02)

Request for Continued Examination Transmittal Letter

Application No. 09/530,260Attorney's Docket No. 001560-381

Page 2

CLAIMS					
	NO. OF CLAIMS	HIGHEST NO. OF CLAIMS THUS PAID FOR	EXTRA CLAIMS	RATE	FEE
Basic Fee					\$750.00 (1001)
Total Claims	37	MINUS 20 =		× \$18.00 (1202) =	
Independent Claims	4	MINUS 3 =		× \$84.00 (1201) =	
If multiple dependent claims are presented, add \$280.00 (1203)					
Total Fee					
If small entity status is claimed, subtract 50% of Total Fee					
TOTAL FEE DUE					

4. ☒ A check in the amount of \$ 750.00 is enclosed for the fee due.
5. ☐ Charge \$ _____ to Deposit Account No. 02-4800 for the fee due.
6. ☐ Applicant(s) requests suspension of action by the Office until at least __, which does not exceed three months from the filing of this RCE, in accordance with 37 C.F.R. § 1.103(c). The required fee under 37 C.F.R. § 1.17(i) is enclosed.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: Jay F. Williams

Jay F. Williams

Registration No. 48,036

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: March 27, 2003



Patent
Attorney's Docket No. 001560-381

[Handwritten signature]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
)
Kengo AKIMOTO et al.) Group Art Unit: 1651
)
Application No.: 09/530,260) Examiner: Irene Marx
)
Filed: July 12, 2000) Confirmation No.: 7267
)
For: PROCESS FOR PRODUCING)
ARACHIDONIC ACID-)
CONTAINING LIPID AND)
DIHOMO-GAMMA-LINOLENIC)
ACID-CONTAINING LIPID)

RECEIVED

APR 01 2003

SUPPLEMENTAL REPLY

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In furtherance to the Amendment and Reply filed January 27, 2003 and in response to the Official Action mailed on July 25, 2002 (i.e., Paper No. 13), Applicants herein provide the following remarks:

REMARKS

Entry of the foregoing, reexamination and further and favorable reconsideration of the subject application in light of the following remarks, pursuant to and consistent with 37 C.F.R. § 1.112, are respectfully requested.

In furtherance to the arguments set forth in the January 27, 2003 Amendment and Reply, Applicants herein provide a signed declaration pursuant to 37 C.F.R. § 1.808 regarding the restrictions on the availability of the deposited biological material. This declaration is in further response to the rejection of claims 36 and 37 under 35 U.S.C.